Endobronchial Valve System Market Overview

Endobronchial Valve System Market is growing at a CAGR of 7% during the forecast period 2024-2031.

Endobronchial valve systems are one-way bronchoscopic valves implanted to occlude airways feeding diseased lung segments most commonly used for bronchoscopic lung volume reduction in severe emphysema and for managing persistent air leaks (bronchopleural/bronchoalveolar fistulas). The public executive summary for the DataM Intelligence report notes the market is growing as clinical adoption increases and regulatory clearances for key valve systems expand.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/endobronchial-valve-system-market

Executive summary

Two commercial valve systems (Pulmonx’s Zephyr and Olympus’s Spiration) have driven much of the clinical and commercial adoption, with Zephyr holding breakthrough/expedited status in the U.S. and Spiration widely used for targeted lobar treatment. The devices differ in shape and mechanism (duckbill vs umbrella), but both offer a minimally invasive alternative to surgical lung-volume reduction in selected emphysema patients and provide an option for persistent air-leak management.

Why the market matters

• Clinical alternative to surgery: Endobronchial valves let physicians achieve lung-volume reduction with bronchoscopy instead of open surgery for select patients, lowering peri-operative morbidity in appropriately selected cases.
• Unmet needs in severe emphysema & persistent air leaks: The rising prevalence of COPD/emphysema and variable outcomes with conservative care create a durable addressable population for valve therapies.
• Device innovation & regulatory momentum: FDA breakthrough designations and approvals have sped clinical uptake and stimulated product development and trials.

Market drivers

• Rising adoption for severe emphysema as clinicians seek less-invasive lung-volume reduction options.
• Clinical evidence of improved patient outcomes (better lung function, symptomatic relief, improved quality of life in responders) that supports broader use at tertiary centers.
• Growing network of specialized interventional pulmonology and stroke/critical-care programs able to perform advanced bronchoscopic procedures.

Restraints & challenges

• Procedure-related complications and device migration — these safety issues and case selection complexity limit adoption in some centers.
• High device & procedure costs — affordability and reimbursement remain barriers in price-sensitive markets.
• Need for robust evidence and appropriate patient selection tools (e.g., collateral ventilation assessment) to predict responders and justify therapy.

Product & segment snapshot

• Device shape: Umbrella-shaped valves (e.g., Spiration) and duckbill-shaped valves (e.g., Zephyr) are the primary device forms identified in market segmentation.
• Applications: Emphysema (lung-volume reduction), COPD care, treatment of persistent air leaks and other niche bronchoscopic indications.
• End-users: Hospitals, specialty pulmonary clinics, academic research centres and ambulatory surgical centres performing bronchoscopic interventions.

Regional outlook

• North America — largest market: Strong presence of major device makers, high procedure volumes, and concentrated interventional pulmonary expertise make North America the leading region.
• Asia-Pacific — fastest growing: Expansion of specialized centers and rising awareness of advanced COPD therapies are driving adoption across APAC.
• Europe, Latin America, MEA: Variable uptake depending on reimbursement, specialist training availability, and regulatory timelines.

Competitive landscape & key players

Major players named on the report page include Pulmonx Corporation (Zephyr) and Olympus / Spiration Valve System — with other device developers and smaller medtech firms active in this endovascular/bronchoscopic niche. Competitive differentiation centres on clinical evidence, valve design (migration resistance, ease of placement/removal), and distribution/clinical training networks.

Recent developments & market context

• Regulatory milestones: Pulmonx’s Zephyr received breakthrough device recognition and expedited pathways in the U.S., accelerating clinical availability. Olympus’s Spiration also secured approvals for targeted emphysema indications.
• COVID-19 considerations: Severe COVID-19 pneumonias and related air-leak complications briefly highlighted bronchoscopic valve insertion as a therapeutic option in select cases, impacting clinical demand and case mixes during the pandemic.